BerGenBio Presents Phase II Trial Updates With Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer

The two presentations will outline BerGenBio's Phase II clinical trial (BGB008, NCT03184571) with bemcentinib and Merck's anti-PD-1 therapy pembrolizumab (KEYTRUDA) in patients with advanced non-small cell lung cancer (NSCLC).